 CAMBRIDGE, Mass.--BUSINESS WIRE--Seres Therapeutics, Inc. Nasdaq: MCRB, a leading microbiome therapeutics company, today announced data from their collaboration with the University of Cologne Köln, Germany demonstrating that decreased microbiome diversity in allogeneic hematopoietic stem cell transplantation HSCT recipients is associated with poor clinical outcomes including mortality and increased incidence of intestinal graft-versus-host disease GvHD. The data are being presented in 